Vowel founders Matt Slotkin, Paul Fisher and Andrew Berman
VowelStartup Vowel just came out of stealth mode with a $4.3 million seed investment to challenge the likes of Zoom and Microsoft Teams in the fast-growing video-conferencing market.
Vowel's investors include Amity Ventures, BoxGroup, Company Ventures and Kevin Lin, the cofounder of Twitch.
CEO and co-founder Andrew Berman said Vowel will focus mainly on the enterprise market, telling Business Insider, "Zoom is great for birthday parties, for virtual happy hours. … For us, we're definitely focused on company communications and communication in your workflow on a daily basis."
Here's the pitch deck Vowel used to raise $4.3 million from investors:
Visit Business Insider's homepage for more stories.
Video-conferencing was already a hot space dominated by the likes of Zoom and Microsoft Teams when the founders of Vowel launched the platform in 2018.
Then, the market exploded with the pandemic and the sharp pivot to remote work, opening up new opportunities for the startup, which came out of stealth mode on Wednesday with a seed round of $4.3 million. Its investors include Amity Ventures, BoxGroup, Company Ventures, and Kevin Lin, the cofounder of Twitch.
"When we started this company, it was pre- this dramatic experience in virtual work," CEO and cofounder Andrew Berman told Business Insider. "We were very much focused on this trend of remote work from the beginning."
Vowel will be competing in a growing market that features legacy platforms like Webex and newer players led by Zoom, which became the star video-conferencing platform during the pandemic.
Berman said Vowel is looking to make video-conferencing a more seamless and productive experience for remote workers: "What we've seen in video-conferencing today is, you see me, I see you, we talk and we're done," he said.
The Vowel platform offers features that allow participants to set meetings more conveniently, produce transcripts and annotate meetings in a way that's searchable and easy to follow — even for team members who failed to attend.
Vowel currently has 14 employees based in multiple locations, including San Diego, New York, and Europe.
"We're focused on work," Berman said. "We're focused on how you communicate in your office. Zoom is great for birthday parties, for virtual happy hours. … For us, we're definitely focused on company communications and communication in your workflow on a daily basis."
Here's the pitch deck Vowel used to raise its seed round of $4.3 million:
New York, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cannula Market Research Report by Product, by Material, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913717/?utm_source=GNWThe Global Cannula Market is expected to grow from USD 249.24 Million in 2019 to USD 324.02 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.47%.Market Segmentation & Coverage:This research report categorizes the Cannula to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Product, the Cannula Market studied across Arthroscopy Cannulas, Cardiac Cannulas, Dermatology Cannulas, Nasal Cannulas, and Vascular Cannulas.Based on Material, the Cannula Market studied across Metal Cannulas (Stainless Steel), Plastic (PVC) Cannulas, and Silicone Cannulas.Based on Application, the Cannula Market studied across Cardiovascular Surgery, Cosmetic/Plastic Surgery, General Surgery, Orthopedic Surgery, Oxygen Therapy, and Diabetes Treatment.Based on End User , the Cannula Market studied across Ambulatory Surgical Centers (ASC), Blood Banks and Home Healthcare Facilities, and Hospitals.Based on Geography, the Cannula Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cannula Market including Boston Scientific Corporation, Conmed Corporation, Edward Lifescience Corporation, Maquet Holding B.V. & Co. KG., Medtronic PLC, Smith & Nephew PLC, Smiths Medical, Sorin Group, Teleflex Inc, and Terumo Corporation.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cannula Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Cannula Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cannula Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cannula Market?4. What is the competitive strategic window for opportunities in the Global Cannula Market?5. What are the technology trends and regulatory frameworks in the Global Cannula Market?6. What are the modes and strategic moves considered suitable for entering the Global Cannula Market?Read the full report: https://www.reportlinker.com/p05913717/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________
Hørsholm, Denmark (23 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced several updates related to its planned filing of a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for dovitinib, a pan-tyrosine kinase inhibitor (TKI) that is one of Allarity’s priority programs.
The Company is announcing an update on timing for its originally planned first NDA filing for dovitinib as a treatment for renal cell carcinoma (RCC). This NDA is based on non-inferiority to the approved drug sorafenib. The Company’s preparation of the application itself is progressing as scheduled, however the third-party contract manufacturer of the registration batch of the drug is experiencing delays, in part as a result of the ongoing coronavirus pandemic. A registration batch is a mandatory component of the NDA filing. Due to this reported delay, Allarity is now expecting to file the NDA in 2021.
Separately, the Company remains on track to file its first pre-market approval (PMA) application with the U.S. FDA for the use of the dovitinib DRP® companion diagnostic to select and treat likely responders to the drug. If regulatory authorities provide the expected PMA approval of the Dovitinib DRP® and an NDA approval of dovitinib, the Company believes it can make the drug available to DRP®-selected RCC patients as an effective new therapy to treat their disease.
Dovitinib, originally developed by Novartis, addresses a significant unmet need for improved therapies for the treatment of RCC, and is a potential therapeutic alternative to sorafenib. Annual sales of sorafenib, under the trade name Nexavar®, were approximately USD $715 million in 2018. The global RCC market is projected to grow to USD $6.3 billon by 2022. In addition to the RCC market, dovitinib has promising potential as a monotherapy in a number of other indications, including estrogen receptor (ER) positive metastatic breast cancer, hepatocellular cancer, endometrial cancer and gastrointestinal stromal tumors, as well as in combination therapy with other approved drugs, including immune checkpoint inhibitors.
Steve Carchedi, CEO of the Company, noted “Although we are disappointed with the unanticipated contract manufacturing delay for our priority dovitinib program, and the resulting setback of our planned first NDA filing for this promising cancer therapeutic, we recognize the delays are a result of the ongoing coronavirus pandemic that is affecting many facets of our industry. We remain fully committed to advancing the near-term filing of our first dovitinib NDA towards hopeful U.S. approval and to bringing this beneficial cancer therapeutic to RCC patients. Moreover, we are enthusiastic about remaining on track with our planned PMA filing for the Dovitinib DRP® companion diagnostic this year.”
About Allarity TherapeuticsAllarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; dovitinib, a pan-TKI in post-Phase 3 for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and irofulven, a DNA damaging agent in Phase 2 for prostate cancer.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.
Follow us on social media:Facebook: https://www.facebook.com/AllarityTx/LinkedIn: https://www.linkedin.com/company/allarity/Twitter: https://twitter.com/allaritytx
Forward-looking statementsThis announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 email@example.com
U.S. Mike Beyer Sam Brown Inc. +1 312-961-2502 firstname.lastname@example.org
Certified Adviser:Svensk Kapitalmarknadsgranskning AB, Email: email@example.com. Tel: +46 11 32 30 732
This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 23 October 2020.
Dovitinib Program Updates_Oct 2020